Embla Medical hf: Interim Report Q1 2024
Announcement no. 10/2024 Interim report Q1 2024 23 April 2024 Sveinn Sölvason, President and CEO, comments: “Sales growth was strong in the first quarter or 10% and organic growth was 7%, driven by volume growth in Prosthetics & Neuro Orthotics and Patient Care. Growth was driven by a strong performance in EMEA, but the year started off slowly in Americas and APAC. Financial performance of FIOR & GENTZ, which we acquired in January, was strong in the first quarter post-acquisition and work has begun to leverage our global sales infrastructure to harvest commercial synergies.